Publications by authors named "Javier de Castro"

Claim this Profile
O
Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study.
Susana Hernandez, Esther Conde, Marta Alonso, Daniel Curto, Fatima Duran, Javier De Castro

Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel therapies targeting delta-like ligand 3 (DLL3) in pulmonary and gastroenteropancreatic neuroendocrine carcinomas.
María Alameda-Guijarro, Antonio Rueda-Lara, Gema Martin-Montalvo, Oliver Higuera, Laura Gutiérrez-Sainz, Javier de Castro

Cancer Treat Rev· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline Mutation Analysis and Real-World Impact in a Selected Cohort of Patients with Non-Small Cell Lung Cancer: INHERITY LC Study.
María Zurera, Juan Carlos Laguna, Laura Mezquita, Oliver Higuera, Sebastián Menao, Javier de Castro

Clin Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring of the oncological process for lung cancer in Spain: an expert consensus report.
Javier de Castro, Patricia Alonso-Fernández, José Javier Castrodeza, Ángel Gayete, Florentino Hernando

Clin Transl Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial.
Jordi Remon, Paolo Bironzo, Nicolas Girard, Laurence Bigay-Game, Oscar Juan-Vidal, Javier de Castro

Lancet Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement.
Aylen Vanessa Ospina-Serrano, Jose Luis González-Larriba, Ernest Nadal, Florentino Hernando Trancho, Joaquim Bosch-Barrera, Rafael López-Castro, Javier de Castro

Transl Lung Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 expression scoring using artificial intelligence algorithms in non-small cell lung cancer harbouring ROS1 fusions: potential clinical-biological significance.
Luis Fernando García, Esther Conde, Susana Hernandez, Marta Alonso, Daniel Curto, Javier de Castro

Clin Transl Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain.
Antonio Calles, Mirian Alonso, Paloma Martín-Martorell, Ana Gómez, Javier de Castro

Cancer Treat Res Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.
Ross A Soo, Urania Dafni, Ji-Youn Han, Byoung Chul Cho, Ernest Nadal, Javier de Castro

Clin Cancer Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.
Mariano Provencio, Ernest Nadal, Amelia Insa, Rosario García Campelo, Joaquín Casal, Javier de Castro

Lancet Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.
Marta Molina-Alejandre, Francisco Perea, Virginia Calvo, Cristina Martinez-Toledo, Ernest Nadal, Javier de Castro

J Immunother Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.
Mariano Provencio, Lucía Robado de Lope, Roberto Serna-Blasco, Ernest Nadal, Pilar Diz Tain, Javier de Castro

Lung Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.
Edurne Arriola, Javier de Castro, Rosario García-Campelo, Beatriz Bernárdez, Reyes Bernabé

Clin Drug Investig· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP.
Aylen Vanessa Ospina, Sergio Bolufer Nadal, José Luis Campo-Cañaveral de la Cruz, Jose Luis González Larriba, Ivan Macía Vidueira, Javier de Castro, Rafael López Castro

Clin Transl Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.
Melina Peressini, Rosario Garcia-Campelo, Bartomeu Massuti, Cristina Martí, Manuel Cobo, Javier de Castro

Clin Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management.
Rocío Rosas-Alonso, Julian Colmenarejo-Fernández, Olga Pernía, Miranda Burdiel, Carlos Rodríguez-Antolín, Javier de Castro

Sci Rep· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Fusion Testing in Patients With NSCLC: The RETING Study.
Esther Conde, Susana Hernandez, Jose Luis Rodriguez Carrillo, Rebeca Martinez, Marta Alonso, Javier De Castro

JTO Clin Res Rep· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium.
Nuria Viñolas, Laura Mezquita, Jesús Corral, Manuel Cobo, Francisco Gil-Moncayo, Javier de Castro

Clin Transl Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings: State-of-the-Art Review.
Fadi N Salloum, Carlo G Tocchetti, Pietro Ameri, Hossein Ardehali, Aarti Asnani, Javier de Castro

JACC CardioOncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
Ernest Nadal, Delvys Rodríguez-Abreu, Marta Simó, Bartomeu Massutí, Oscar Juan, Javier De Castro

J Clin Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MiR-151a: a robust endogenous control for normalizing small extracellular vesicle cargo in human cancer.
Miranda Burdiel, Julia Jiménez, Carlos Rodríguez-Antolín, Álvaro García-Guede, Olga Pernía, Javier de Castro

Biomark Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
Mariano Provencio, Ernest Nadal, José L González-Larriba, Alex Martínez-Martí, Reyes Bernabé, Javier de Castro, Rafael López-Castro

N Engl J Med· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
Dolores Isla, María D Lozano, Luis Paz-Ares, Clara Salas, Javier de Castro

Rev Esp Patol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1.
Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Javier De Castro, Amelia Insa, Alex Martínez

J Med Econ· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain.
Javier De Castro, Amelia Insa, Roberto Collado-Borrell, Vicente Escudero-Vilaplana, Alex Martínez

BMC Pulm Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis